Loading...
•
Jun 30, 2024
Bristol-Myers Squibb Q2 2024 Earnings Report
Bristol-Myers Squibb's Q2 2024 financial results reflected continued progress on commercial execution, driving growth portfolio and pipeline advancement.
Key Takeaways
Bristol Myers Squibb reported second quarter revenues of $12.2 billion, a 9% increase (+11% adjusting for foreign exchange). The Growth Portfolio revenues were $5.6 billion, increasing 18% (+21% adjusting for foreign exchange). GAAP EPS was $0.83 and Non-GAAP EPS was $2.07.
Second Quarter Revenues were $12.2 Billion, increasing 9% (+11% Adjusting for Foreign Exchange).
Growth Portfolio Revenues were $5.6 Billion, increasing 18% (+21% Adjusting for Foreign Exchange).
GAAP EPS was $0.83 and Non-GAAP EPS was $2.07; Includes Net Impact of $(0.04) Per Share for GAAP EPS and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income.
Achieved U.S. Approval of Breyanzi in Both Follicular Lymphoma and Mantle Cell Lymphoma; Subcutaneous Nivolumab Under Regulatory Review in the U.S. and E.U.
Revenue by Geographic Location
Forward Guidance
Bristol Myers Squibb is raising portions of its 2024 line-item guidance.
Positive Outlook
- Total Revenues: Upper end of low single-digit range
- Total Revenues (excl. F/X): Upper end of low single-digit range
- Gross Margin %: Between ~74% and ~75%
- Other income/(expense): ~($50M)
- Diluted EPS: $0.60 - $0.90
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...